- Age-related decline in HMGB1-neutralizing IgM autoantibody response impairs resistance to high-fat diet in miceby inmunoadminJ Immunol. 2025 Jul 29:vkaf172. doi: 10.1093/jimmun/vkaf172. Online ahead of print. ABSTRACT As we age, it becomes increasingly important to reduce the consumption of fatty foods. In mice, we also find that after consuming a high-fat diet, older mice develop insulin resistance more easily than young mice. But how aging renders both humans and mice … Read more
- Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeby Ciccone, D. N., Kuo, F.-S., Boiko, S., Carreiro, S., Kaila, N., McElwee, J. J., Tummino, P. J., Loh, C.Background HPK1 (hematopoietic progenitor kinase 1, MAP4K1), an MAP4K serine/threonine kinase family member, is a negative regulator of immune cell function. Genetic HPK1 kinase inactivation or knockout in mice leads to immune cell activation and tumo…
- Complement system modulation in age-related macular degeneration: navigating failures, building future successesby inmunoadminCurr Opin Immunol. 2025 Jul 28;96:102616. doi: 10.1016/j.coi.2025.102616. Online ahead of print. ABSTRACT Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in elderly populations across developed countries. Complement system dysregulation has been implicated in AMD onset and evolution. Complement inhibition therapies have been authorized in the USA as the primary … Read more
- Can we cure vasculitis?by inmunoadminCurr Opin Immunol. 2025 Jul 28;96:102618. doi: 10.1016/j.coi.2025.102618. Online ahead of print. ABSTRACT As with all autoimmune diseases, antineutrophil cytoplasmic autoantibody (ANCA) vasculitis cannot be cured by a singular approach. This complexity arises because autoimmune conditions typically result from multiple hits to the immune system – including genetic predisposition, environmental exposures, infections, and perturbations in … Read more
- IL-7 armed binary CAR T cell strategy to augment potency against solid tumorsby Alejandro G. Torres ChavezIntroductionClinical studies of T cells engineered with chimeric antigen receptor (CAR) targeting CD19 in B-cell malignancies have demonstrated that relapse due to target antigen (CD19) loss or limited CAR T cell persistence is a common occurrence. The…